LakePharma’s Coronavirus Spike Protein Antibodies

A fresh quiver of arrows against the crowned invader!

Webinar Oct 15, 2020  11AM PDT | 2PM EDT   30 Minutes

As part of LakePharma's ongoing effort to combat the COVID-19 pandemic, we have discovered a large collection of over 350 diverse antibodies against the SARS-CoV-2 spike protein.  The SARS-CoV-2 spike protein initiates viral attachment via binding to human angiotensin-converting enzyme 2 (ACE2), thus presenting itself as a crucial candidate for COVID-19 therapeutics, diagnostics, and vaccines.  

Following immunization of our immunologically diverse PentaMiceTM, antibodies were obtained using our hybridoma-based antibody recovery workflow.  Based on extensive screening assays, LakePharma’s SARS-CoV-2 spike antibodies display a wide range of binding specificities and functional properties.  The spike antibodies can be grouped according to reactivity profiles based on binding to the receptor binding domain (RBD) and/or S1 or S2 domains; blocking spike protein binding to the ACE2 receptor; neutralizing SARS-CoV-2 pseudovirus infection of ACE2+TMPRSS2+ target cells; and cross-reactivity (or lack thereof) with spike proteins from other coronaviruses (SARS, MERS, and HKU1).

The various reactivity and functional profiles are consistent with COVID-19 antibody therapy, prevention of SARS-CoV-2 infection, and selective SARS-CoV-2 detection diagnostics.  These antibodies are available for licensing for either therapeutic or diagnostic application. If you are interested in augmenting an existing COVID-19 antibody-based therapeutic or diagnostic program, or jumpstarting an early stage proof-of-concept treatment/prevention/detection paradigm, please join the webinar to learn more.


Brian Zabel, Ph.D.
Senior Director, Discovery Immunology


Brian Zabel, Ph.D. received BS degrees in Biology and Mathematics from the Massachusetts Institute of Technology in 1997 and a PhD in Immunology from Stanford University in 2004. Dr. Zabel holds nine US patents and has published more than 50 peer reviewed research articles in high impact journals such as the Journal of Experimental Medicine. Dr. Zabel has special expertise in hybridoma-based monoclonal antibody discovery, with demonstrated success against challenging targets. At LakePharma, Dr. Zabel leads a scientific team of hybridoma experts in the discovery of therapeutic and diagnostic antibodies.

© 2020 LakePharma Inc.